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Abstract—Novel coumarinic derivatives were synthesized and tested for their inhibitory potency toward a-CT and HLE. Cycloalkyl
esters and amides were found to be essentially inactive on both enzymes. On the opposite, aromatic esters strongly inactivated a-CT
whereas HLE was less eciently inhibited with dichlorophenyl ester derivatives (kinact/KI=4000M
ÿ1 sÿ1 for 36). Representative
examples of amide, ester, thioester and ketone derivatives were prepared in order to evaluate the influence of the link between the
coumarinic ring and the phenyl side chain. The irreversible inactivation of a-CT by 6-chloromethyl derivatives should be due to
alkylation of a histidine residue as suggested by the amino acid analysis of the modified chymotrypsin. Conversely the inhibition of
HLE was transient. Intrinsic reactivity of coumarins has been calculated using a model of a nucleophilic reaction between the ligand
and the couple methanol–water. From this calculation, it appears that dierences in the inhibitory potency expressed by these
molecules cannot only be explained by dierences in the reactivity of the lactonic carbonyl group toward the nucleophilic attack.
# 2000 Elsevier Science Ltd. All rights reserved.
Introduction
Serine proteases are attractive targets for the design of
enzyme inhibitors since they are involved in the etiology
of several diseases.1ÿ3 Within the class of serine pro-
teases, bovine a-chymotrypsin (a-CT) constitutes an
interesting biological tool for the evaluation of new
synthetic inhibitors and may be helpful for the design of
new therapeutical tools directed against chymotrypsin-
like proteases such as cathepsin G and mast cell chy-
mases. Cathepsin G is implicated in inflammation and
mast cell chymases in allergic responses and psoriasis.1
Human leukocyte elastase (HLE) is potentially one of
the most harmful enzymes in the body. HLE hydrolyzes
a wide variety of proteins, including the structural
fibronectin, collagen and elastin.2 Under physiological
conditions, the destructive eects of HLE are limited
to the microenvironment immediately surrounding
the neutrophils by endogenous proteinase inhibitors
(a-1-proteinase inhibitor, secretory-leukoproteinase
inhibitor, elafin). The imbalance between proteases
and antiproteases leads to uncontrolled tissue destruc-
tion by HLE, which is implicated in the promotion or
the exacerbation of a number of diseases including acute
respiratory distress syndrome, rheumatoid arthritis,
atherosclerosis, pulmonary emphysema and cystic
fibrosis.4ÿ8
A number of low molecular weight inhibitors of chymo-
trypsin and elastase-like proteinases have been reported
as mechanism-based inhibitors. These include halo enol
lactones,9ÿ11 b-lactams,12ÿ16 saccharin derivatives,17,18
benzoxazinones,19,20 substituted isocoumarins,21ÿ23 halo-
methyldihydrocoumarins24,25 and thiadiazolidinones.26,27
We previously described the development of coumarinic
derivatives28 characterized by an alkyl, aryl ester (1) or
amide (2) function in the position 3 (Fig. 1). The elec-
trophilic chloromethyl moiety in the position 6 was
required to irreversibly inhibit a-CT. This is consistent
with a mechanism in which the lactone group undergoes
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the nucleophilic attack of the active serine residue (Fig.
2). After the ring opening, the elimination of HX from
the benzylic derivative is a fast reaction in mild condi-
tions when X is a good leaving group such as a chlor-
ine.29 The resulting electrophilic quinone methide could
form a covalent bond with a nucleophilic residue such
as His-57 or Met-192 located within the enzyme recog-
nition site. Structure–activity relationships established
that the nature of the substituent in position 3 strongly
influences the inhibitory potency on the serine protease.
According to these considerations, we modulated the
coumarinic template in order to improve the inhibitory
potency. In the present work, we report the synthesis
and the inhibition studies of new cycloalkyl or aryl
esters and amides of 6-chloromethyl-2-oxo-2H-1-ben-
zopyran-3-carboxylic acid. The nature of the substitu-
tion on the phenyl side chain was also studied as well as
its link to the coumarinic ring. Finally, the interest of
the 6-chloromethyl moiety was further investigated.
Intrinsic reactivity has been calculated using a model of
a nucleophilic reaction between the ligand and the couple
methanol–water.30 The postulated mechanism involves
an alkylation within the active site; we performed an
amino acid analysis of the modified a-CT in order to
determine which amino acid residue was alkylated.
Chemistry
Generally, the acyl chloride of 6-chloromethyl-2-oxo-
2H-1-benzopyran-3-carboxylic acid 6 was obtained by
treatment of the starting compound 5 with thionyl
chloride (Scheme 1). This intermediate 6 was then con-
verted into esters (11–15, 26–37), amides (16–25, 38, 40)
or thioesters (39, 41) by reaction with the appropriate
alcohol, amine or thiol, respectively.
Compound 10 (Scheme 2) was prepared from 5-(hydroxy-
methyl)salicylaldehyde (7), which reacted with ethyl
benzoylacetate (8) in a Knoevenagel-type reaction leading
to 3-benzoyl-6-(hydroxymethyl)-2H-1-benzopyren-2-one
(9). Treatment of 9 with thionyl chloride led to 3-benz-
oyl-6-(chloromethyl)-2H-1-benzopyren-2-one (10).
Products 42–47 were prepared from the appropriate
carboxylic acid by treatment with thionyl chloride
and then with phenol, or 3-chlorophenol, respectively
(Scheme 3).
Results and Discussion
The newly synthesized compounds were examined on a-
CT and HLE either by the preincubation method or by
the progress curve method (Tables 1–4). These cou-
marin derivatives were expected to act as irreversible
inhibitors of a-CT.
In the cycloalkyl ester series, only 11 and 14 (kinact/KI
470 and 3300Mÿ1 sÿ1, respectively) weakly inhibited a-
CT (Table 1). The cycloalkyl amide derivatives (16–25)
failed to inhibit a-CT and HLE. These results confirm
the influence on the inactivation process of the nature of
the substituent at the C-3 position; the presence of an
aromatic moiety strongly improves the inhibition.28
Consequently, we focused our works on aryl ester deri-
vatives by analyzing the eect on inhibition of sub-
stituent on the aromatic moiety. The compounds 26–34
and 36 behaved as time-dependent inhibitors of a-CT
and HLE, whereas 35 was found to be inactive (Table
2). A strong inactivation was observed with derivatives
bearing a single halide or a methoxy group located in
the meta position (28–31). The presence of a second
substituent on the phenyl ring did not improve the
inhibitory activity toward a-CT (32–36). However, the
inhibitory potency toward HLE was increased with the
dichlorophenyl ester derivatives 34 and 36. Since no
spontaneous and hydroxylamine-mediated reactivations
of the enzyme were observed, the a-CT inhibition
encountered with these coumarinic derivatives was con-
sidered to be irreversible. This phenomenon can be
explained by a second hit mechanism (Fig. 2). After the
Figure 1. Chemical structures of 6-chloromethylcoumarin esters (1),
amides (2), thioesters (3) and ketones (4).
Figure 2. Postulated mechanism for the inactivation of a-chymo-
trypsin by coumarinic derivatives.
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nucleophilic attack of the lactonic carbonyl ring and the
formation of the acyl enzyme, alkylation of the active
site His-57 residue could occur as a consequence of
the quinone methide formation resulting from the halo-
gen ion elimination. On the opposite, the inhibition of
HLE by coumarin derivatives is transient as evidenced
by the slow and complete reactivation within 20 h of the
enzyme treated with compound 36. This reactivation of
the enzyme, speeded up by treatment with hydroxyl-
amine, supports, therefore, the formation of a stable
acyl-enzyme, suggesting that these inhibitors act as
alternate substrates of HLE. Consequently, the values
of kobs/[I] reported in Tables 1–4 correspond to the
acylation step.
In order to evaluate the importance of the link between
the coumarinic ring and the phenyl residue, we prepared
representative examples of amide, ester, thioester and
ketone compounds which were tested for their inhibi-
tory potency toward a-CT and HLE (Fig. 3A and
Tables 1–3). As compared to their ester counterparts,
the two derivatives with an amide link were found to
be inactive (37 versus 38 and 31 versus 40). The absence
of any inhibitory potency expressed by these amide
derivatives could be related to the formation of a strong
intramolecular hydrogen bond between the oxygen
atom of the lactonic carbonyl and the proton of the
amide nitrogen atom. As developed further, this hydro-
gen bond induces a more restricted conformational
mobility of the amide side chain. Interestingly, the
inactivation potency of the m-chlorophenyl thioester
derivative toward a-CT was in the same range as that
of the corresponding ester (31 versus 41). Replacement
of the ester function by a ketone group led to an
important decrease of the inhibitory potency (37 versus
10).
However, it was interesting to note that 10 is still an
inactivator, in agreement with a reaction of the active
serine with the carbonyl group of the lactone. The par-
tition ratio r which represents the average number of
enzyme ‘turnovers per inactivation’ (kc/kinact) was
determined for the inhibition of a-CT by some of the
most powerful inactivators 31, 34, 36 and 41 and was
found equal to 1.8, 2.4, 6.3 and 1.05, respectively (Fig.
3B). As a result, the partition ratio of thioester 41 is
close to that of an optimal inhibitor (an ideal suicide
substrate would display an r value equal to 0).
Scheme 1. Reagents: (i) SOCl2; (ii) ROH/pyridine/dioxane; (iii) RR
0NH/pyridine/dioxane; (iv) RSH/pyridine/dioxane.
Scheme 2. Reagents: (i) piperidine/EtOH; (ii) SOCl2.
Scheme 3. Reagents: (i) SOCl2; (ii) ROH/pyridine/dioxane.
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Phenyl 6-methyl-2-oxo-2H-1-benzopyran-3-carboxylate
(42), the non-halogenated analogue of 37, was found to
be inactive on a-CT, indicating that the halomethyl
moiety is required to obtain an irreversible inactivation
of a-CT (Table 4). In order to confirm this result, we
prepared esters 43–47 of 2-oxo-2H-1-benzopyran-3-car-
boxylic acid substituted in the position 6 with a group
devoid of a latent alkylating function or bearing a
potentially poor leaving group (acetate) (Table 4).
Compounds 42 and 43 did not inactivate a-CT and
behaved as substrates (kcat/Km=11,600 M
ÿ1 sÿ1 for 42).
Nevertheless, compound 45 inactivated a-CT (kinact/
KI= 9400M
ÿ1 sÿ1). This could be explained by the
formation of a stable acyl-enzyme (no possibility to
unmask an alkylating function). The substitution at the
meta position by a chlorine atom strongly influenced the
interaction of coumarins with a-CT (45/42, 46/43, 47/
44). The inactivation of a-CT by 47 was found to be
irreversible with a poor partition ratio (r=80). The
corresponding 6-chloromethyl analogue 31 led to a
smaller value of r (r=1.8). This may be due to a less
nucleofugal leaving group [pKa(acetate)=4.76 and
pKa(Cl)=ÿ6.1]. With other series of suicide substrates,
it has been reported that acetate, as a leaving group,
does not lead to irreversible inhibition.16,31ÿ33 In the a-
CT recognition site, two amino acids may be alkylated:
Table 1. Kinetic parameters for the inactivation of a-CT (pH 7.5 and
25 C) and HLE (pH 8.0 and 25 C) by alkyl ester and amide deriva-
tivesa




11 O-C6H11 470 ni
12 O-C7H13 ni
b ni
13 O-C8H15 ni ni
14 O-C12H23 3300 ni
15 O-1-Methyl-piperid-3-yl 45 ni
16 NH-C3H5 ni ni
17 NH-C5H9 ni ni
18 NH-C6H11 ni ni
19 NH-C7H13 ni ni
20 NH-C8H15 ni ni
21 NH-C12H23 ni ni
22 NH-Piperid-1-yl ni ni
23 N(C3H7)2 ni ni
24 1-Piperidinyl ni ni
25 4-Morpholinyl ni ni
aStandard errors are less than 15%.
bNo inactivation at 10 mM.
Table 2. Kinetic parameters for the inactivation of a-CT (pH 7.5 and
25 C) and HLE (pH 8.0 and 25 C) by aryl ester derivativesa




26 20-NO2 10,200b 1250
27 30-CF3 <500d 330
28 30-OCH3 188,500b 98
29 30-F 242,000 440
30 30-Br 560,000 290
31c 30-Cl 762,700 630
32 30-Cl-50-OCH3 1200d 330
33 20-Cl-30-Cl 1200d <200
34 20-Cl-50-Cl 288,000 2700b
35 20-Cl-60-Cl nie <200
36 30-Cl-50-Cl 110,000 4000
aStandard errors are less than 15%.
b26/CT: kinact=0.052 s
ÿ1; KI=5.1mM. 28/CT: kinact=0.0245 sÿ1;
KI=0.13mM. 34/HLE: kinact=0.006 sÿ1; KI=2.2mM.
cData from ref 28.
dObtained as kobs/[I] at low inhibitor concentration.
eNo inactivation at 10 mM.
Table 3. Kinetic parameters for the inactivation of a-CT (pH 7.5 and
25 C) and HLE (pH 8.0 and 25 C) by phenyl ester, phenyl amide,
phenyl thioester or phenyl ketone derivativesa




37b COO H 100,000 23
38b CONH H 32 nic
39 COS H 39,000 ni
10 CO H 2430 ni
31b COO Cl 762,700 630
40 CONH Cl ni ni
41 COS Cl 730,000 <200
aStandard errors are less than 15%.
bData from ref 28.
cNo inactivation at 10 mM.
Table 4. Kinetic parameters for the inactivation of a-CT (pH 7.5 and
25 C) and HLE (pH 8.0 and 25 C) by phenyl or chlorophenyl esters
of 6-substituted 2-oxo-2H-1-benzopyran-3-carboxylic acida
Compound
no.




42b CH3 H ni
c 330
43 H H ni 34
44 CH2OCOCH3 H ni ni
45 CH3 Cl 9400 1100
46 H Cl <500 610
47 CH2OCOCH3 Cl 20,000
d 1440
aStandard errors are less than 15%.
bData from ref 28.
cNo inactivation at 10 mM.
d47/CT: kinact=0.028 s
ÿ1, KI=1.4mM.
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catalytic His-57 or Met-192, which caps the primary
specificity pocket. The amino acid analysis of native
enzyme and enzyme modified by 31 and 34 showed a
decrease of the histidine content from 2 residues to 1
with no change in the methionine content. This demon-
strates that a histidine residue has been modified and
that the inactivation of a-CT may be due to the mod-
ification of His-57. Interestingly, the 3-chlorophenyl
esters 45–47 were found to inhibit HLE with an e-
ciency equal or superior to that of the 6-chloromethyl-
substituted analogue 31. This indicated that the pre-
sence of an alkylating group was not required for the
inhibition of HLE. This result might be explained by an
alternative mode of action. An adequate proximity
between the alkylating moiety of the drug and the cata-
lytic histidine should not be realized in the active site of
HLE. It should also be speculated that HLE attacks at
the exocyclic ester group instead of the lactone.34
Optimized geometries of the ligand
After optimization, 37 revealed two minimal energetic
geometries with respect to the dihedral angle C2-C3-C14-
X16 value (Table 5). These minima correspond to two
conformations (a and b) characterized by an opposite
value for this dihedral angle. The most stable b-con-
formation of 37 is close to that observed in the X-ray
structure of 30, where both carbonyl groups point in the
same direction (Fig. 4). The energetic level of the tran-
sition state structure (TS) between the two conformers is
only 3.3 kcal/mol and it can be assumed that equili-
brium between both of them could exist. The same fea-
ture occurs for the thioester 39. On the contrary, the
amide function in 38 highly stabilizes the conformer a
by an internal H-bond (C2O......HN16, Table 5 and Fig.
5). A first TS is located before the minimum b1 which
itself is separated from a symmetrical other one by a
second TS located at 11 kcal/mol from the first mini-
mum. Thus, it clearly appears that the side chain in the
position 3 of the amide 38 exhibits a lower conforma-
tional freedom than that calculated for the correspond-
ing ester 37 and the thioester 39.
Nucleophilic model of the intrinsic reactivity
Ab initio calculation led us to determine the energetic
barrier (E) required to reach the transition state
structure in an interaction model involving the ligand
and the couple methanol–water used as nucleophile
(Fig. 6 and Table 6). As an example, the two minimum
conformations of the amide 38 and their respective
geometry at the transition state are given in Figure 7.
This approach has been successfully applied in the study
of the acylation mechanism of a-chymotrypsin.30 The
activation barrier for the lactone ring 48 comprising two
conjugated double bonds is significantly higher than
that calculated for methyl formate taken as reference.30
Figure 3. Inactivation of a-CT by compound 41 at pH 7.5 and 25 C. A. Determination of the constant ki/KI by the progress curve analysis. Plot of
p versus [I]0. B. Determination of the partition ratio. Plot of the remaining activity (%) at infinite time versus [I]0/[E]0.
Table 5. Optimized values of the dihedral angle f and calculated E
values relative to the a conformation for the ester, the amide and the
thioester
Compounds Conformer f () Ea (kcal/mol)
Crystal 30 ÿ161.2
X16=O




38 a 0.0 0.000




39 a 4.0 0.000
X16=S TS 88.0 2.945
b ÿ156.0 0.217
aThe energy level of conformer a was set to 0.
bTS: transition state.
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By introducing a phenoxycarbonyl moiety in the posi-
tion 3 of the lactone ring 49, the E value is lowered
and reflects a higher intrinsic reactivity of the lactonic
carbonyl function. This could be explained by the elec-
tron withdrawing eect of the phenoxycarbonyl group.
Adjunction of a benzene ring to the lactone 48 leading
to coumarin 50 slightly increases the reactivity. The
intrinsic reactivity of the 6-chloromethyl-substituted
coumarinic compound 51 is also improved when com-
pared to the lactone ring alone (48) or the coumarin 50.
Association of the coumarinic structure with a phenoxy-
carbonyl moiety in the position 3 (52) leads to a theo-
retical intrinsic reactivity slightly lower than that of 37,
which includes a chloromethyl substituent. Thus, a
coumarinic compound bearing a 3-phenoxycarbonyl
and/or a 6-chloromethyl group may have a higher reac-
tivity compared to the simple coumarinic derivative 50,
devoid of both substituents. These results also confirm
that the coumarinic core structure like 37 should have
the appropriate reactivity for interacting with serine
enzymes. Further calculations have been made in order
to appreciate the influence of the position of the chlor-
ine atom on the phenyl ring. As observed in Figure 6,
only slight dierences are noted between compounds 53,
31 and 54. Their E is similar or lower to that of 37,
devoid of this halogen atom. Indeed, a slight increase of
the intrinsic reactivity is only noted for 53, the ortho
chloride derivative. By comparison with compound 53,
the energy barrier of the 2,6-dichloro substituted deri-
vative 35 is slightly increased and that of compound 33
is decreased. Even though the intrinsic reactivity of all
the mono- and di-chloro derivatives remains in the the
same energetic range, the inhibitory potency greatly
diers. For example, the 2,6-dichloro substituted deri-
vative 35 is inactive against a-CT whereas the 2,5-
dichloro 34 is very potent (Table 2). Consequently, dif-
ferences in the inhibitory activity expressed by these
chlorophenyl or dichlorophenyl molecules (Table 2 and
ref 35) cannot be only explained by dierences in the
reactivity of the lactonic carbonyl group involved in the
nucleophilic attack. The most important geometric fea-
ture which could explain the marked variations in the
kinetic parameters toward a-CT is probably related to
the preferential conformation adopted by the sub-
stituted phenoxycarbonyl side chain. Finally, the exam-
ination of the antiparallel a conformer and parallel b
conformer of 38 led to the conclusion that the con-
formation 38a gave a significantly higher reactivity of
the lactonic carbonyl compared to the conformation
38b (Table 6 and Fig. 7). This phenomenon is directly
related to the stabilization of the partially negatively
charged O carbonyl by the neighboring H–N amide
group (Fig. 7). However, even if the theoretical reactiv-
ity of the amide 38a was higher than the corresponding
ester 37, the lack of inhibitory activity of 38 should be
explained by the restricted conformational freedom of
the amide, which should be responsible for a lowering of
the recognition adaptability during receptor site inter-
action. Regarding compounds 37 and 39, no dierences
are noted for the activation energy of a and b (Table 6).
Figure 4. ORTEP representation of X-ray structure of 30.
Figure 5. Conformational study of the amide 38.
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Conclusion
The ester and thioester coumarinic derivatives possess
the structural requirements to act as ecient inactiva-
tors of serine proteases. The lack of inhibitory activity
of the amide derivatives should be explained by a poor
recognition of the molecule by the enzyme rather than
by a lack of reactivity toward nucleophilic addition. The
determination of intrinsic reactivity of the lactone indi-
cates that the potency of the phenyl derivatives is rather
due to the conformation of the phenoxycarbonyl side
chain than the intrinsic reactivity of the lactone. In
order to support this theoretical approach, the kinetic
parameters of alkaline hydrolysis of these coumarins
could be helpful.36,37 The irreversible inactivation of
a-CT by these compounds probably implies an alkyla-
tion of a histidine residue in the receptor site. On the
contrary, the inactivation of HLE was transient and the
enzyme slowly recovered its activity. The modulation of
substituents in the position 3 and in the position 6 opens
the way for the design of selective inhibitors of HLE.
Experimental
Chemistry
Melting points were determined with a Bu¨chi-Tottoli
apparatus in open capillary tubes and are uncorrected.
Analyses (C, H, N) were performed on a Carbo-Erba
analyzer and were within 0.4% of the theoretical
values. The IR spectra were recorded in KBr on a
Perkin–Elmer 1750 spectrophotometer. The 1H NMR
spectra were recorded in CDCl3 (or DMSO-d6) on a
Bruker AW 80 (80MHz) or a Jeol JNM-EX 400
(400MHz). TMS was used as an internal standard and
chemical shifts are reported in d values (ppm) relative to
internal TMS.
Figure 6. Intrinsic reactivity of the nucleophilic reaction.
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3-Benzoyl-6-(hydroxymethyl)-2H-1-benzopyren-2-one (9).
A mixture of 5-(hydroxymethyl)salicylaldehyde (7)
(0.76 g, 5mmol), ethyl benzoylacetate (8, 1.056 g,
5.5mmol), piperidine (0.1mL) and ethanol (5mL) was
refluxed for 10min. After cooling, the precipitate was
collected and washed with ethanol to give the title
compound (0.63 g, 45%): mp 170–172 C; IR 3031 (C–H
arom), 1712 (CO lactone), 1671 (CO ketone), 1624,
1581, 1269 cmÿ1; 1H NMR (400MHz, CDCl3, TMS), d
4.80 (s, 2H, CH2OH), 7.41 (d, 1H, 8-H), 7.49 (dd, 2H,
30-H, 50-H), 7.61–7.65 (m, 3H, 20-H, 40-H, 60-H), 7.88 (s,




(1 g; 3.57mmol) was heated in thionyl chloride (10mL)
for 3 h. The resulting solution was concentrated
under reduced pressure and the residue was dispersed in
dry toluene (10mL). After elimination of the solvent
under reduced pressure, the residue of crude 10 was
recrystallized in ethyl actetate:petroleum ether 40–
60 C to give the title compound (0.87 g, 82%): mp 178–
179 C; IR 3067 (C–H arom), 1712 (CO lactone), 1662
(CO ketone), 1624, 1575, 1251 cmÿ1; 1H NMR
(400MHz, CDCl3, TMS), d 4.66 (s, 2H, CH2Cl), 7.42
(d, 1H, 8-H), 7.50 (dd, 2H, 30-H, 50-H), 7.61–7.69 (m,
3H, 20-H, 40-H, 60-H), 7.88 (s, 1H, 5-H), 7.89 (d, 1H, 7-
H), 8.07 (s, 1H, 4-H). Anal. (C17H11O3Cl) C, H.
General procedure for the preparation of the esters
(11–15, 31, 37), thioesters (39, 41) and amides (16–25,
38, 40) of 6-chloromethyl-2-oxo-2H-1-benzopyran-3-
carboxylic acid, of the esters of 2-oxo-2H-1-benzo-
pyran-3-carboxylic acid (43, 46) and of the esters of
6-acetoxymethyl- (44, 47) and 6-methyl-2-oxo-2H-1-
benzopyran-3-carboxylic acids (42, 45)
The appropriate coumarinic acid (1 g) was suspended in
thionyl chloride (10mL) for 3 h. The resulting solution
was evaporated to dryness under reduced pressure
and the residue was dispersed in dry toluene (10mL).
The solvent was eliminated under reduced pressure.
Dispersion in dry toluene and solvent elimination was
repeated twice. The residue reacted with the appropriate
alcohol (1.1 equiv), amine (1.1 equiv) or thiol (1.1 equiv)
in the presence of anhydrous pyridine as previously
described.28
Cyclohexyl 6-(chloromethyl)-2-oxo-2H-1-benzopyran-3-
carboxylate (11). This was prepared according to the
general procedure (yield: 47%): mp 185–186 C (ethyl
acetate); IR 3064 (C–H arom), 2939, 2860 (C–H aliph),
1743 (CO ester), 1712 (CO lactone), 1628, 1580,
1274, 1256 cmÿ1; 1H NMR (80MHz, CDCl3/DMSO,
HMDS), d 1.25–1.85 (m, 10H, (CH2)5), 4.55 (s, 2H,
CH2Cl), 5.00 (m, 1H, CH), 7.30 (d, 1H, 8-H), 7.55 (s,
1H, 5-H), 7.60 (d, 1H, 7-H), 8.35 (s, 1H, 4-H). Anal.
(C17H17O4Cl) C, H.
Figure 7. The two minimum conformations of the amide and their
respective geometries at the transition state during the reaction with
the couple methanol–water.
Table 6. Activation energy of the nucleophilic reaction
Compounds Conformer f () Ea (kcal/mol)





38 a 0.0 0.000
X16=NH TS 14.0 29.152
b1 142.0 0.000
TS 139.0 32.225
39 a 4.0 0.000
X16=S TS 5.0 33.376
b ÿ156.0 0.000
TS 155.0 32.980
aThe energy level of each minimum conformer was fixed to 0 kcal/mol.
bTransition state.
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Cycloheptyl 6-(chloromethyl)-2-oxo-2H-1-benzopyran-3-
carboxylate (12). This was prepared according to the
general procedure (yield: 28%): mp 171–174 C (ethyl
acetate); IR 3062 (C–H arom), 2932, 2855 (C–H aliph),
1743 (CO ester), 1708 (CO lactone), 1628, 1580,
1273, 1256 cmÿ1; 1H NMR (80MHz, CDCl3, HMDS),
d 1.35–1.80 (m, 12H, (CH2)6), 4.55 (s, 2H, CH2Cl), 5.55
(m, 1H, CH), 7.25 (d, 1H, 8-H), 7.50 (s, 1H, 5-H), 7.55
(d, 1H, 7-H), 8.35 (s, 1H, 4-H). Anal. (C18H19O4Cl)
C, H.
Cyclooctyl 6-(chloromethyl)-2-oxo-2H-1-benzopyran-3-
carboxylate (13). This was prepared according to the
general procedure (yield: 35%): mp 169–170 C (ethyl
acetate:petroleum ether 40–60 C); IR 3061 (C–H
arom), 2925, 2853 (C–H aliph), 1742 (CO ester), 1708
(CO lactone), 1627, 1580, 1274, 1256 cmÿ1; 1H NMR
(80MHz, CDCl3, HMDS), d 1.40–1.80 (m, 14H,
(CH2)7), 4.55 (s, 2H, CH2Cl), 5.10 (m, 1H, CH), 7.25 (d,
1H, 8-H), 7.50 (s, 1H, 5-H), 7.55 (d, 1H, 7-H), 8.30 (s,
1H, 4-H). Anal. (C19H21O4Cl) C, H.
Cyclododecyl 6-(chloromethyl)-2-oxo-2H-1-benzopyran-
3-carboxylate (14). This was prepared according to the
general procedure (yield: 58%): mp 164–167 C (ethyl
acetate:petroleum ether 40–60 C); IR 3051 (C–H
arom), 2928, 2864 (C–H aliph), 1747 (CO ester), 1699
(CO lactone), 1623, 1578, 1475, 1304, 1272, 1255
cmÿ1; 1H NMR (80MHz, CDCl3, HMDS), d 1.10–1.70
(m, 22H, (CH2)11), 4.55 (s, 2H, CH2Cl), 5.20 (m, 1H,
CH), 7.25 (d, 1H, 8-H), 7.55 (s, 1H, 5-H), 7.60 (d, 1H, 7-
H), 8.35 (s, 1H, 4-H). Anal. (C23H29O4Cl) C, H.
1-Methylpiperid-3-yl 6-(chloromethyl)-2-oxo-2H-1-benzo-
pyran-3-carboxylate (15). This was prepared according
to the general procedure (yield: 26%): mp 217 C dec.
(ethyl acetate:petroleum ether 40–60 C); IR 3058 (C–H
arom), 2940, 2778 (C–H aliph), 1742 (CO ester), 1714
(CO lactone), 1630, 1581, 1273, 1255 cmÿ1; 1H NMR
(400MHz, CDCl3, TMS), d 1.75 (m, 2H, 50-H), 2.32 (s,
3H, CH3,) 2.45–2.76 (m, 6H, 2
0-H, 40-H, 60-H), 4.64 (s,
2H, CH2Cl), 5.15–5.17 (m, 1H, 3
0-H), 7.35 (d, 1H, 8-H),
7.65–7.66 (d+s, 2H, 5-H, 7-H), 8.54 (s, 1H, 4-H). Anal.
(C17H18NO4Cl) C, H, N.
N-Cyclopropyl-6-(chloromethyl)-2-oxo-2H-1-benzopyran-
3-carboxamide (16). This was prepared according to the
general procedure (yield: 54%): mp 222–225 C (ethyl
acetate:petroleum ether 40–60 C); IR 3294 (N–H), 3046
(C–H arom), 1728 (CO lactone), 1651 (CO amide),
1612, 1574, 1519 cmÿ1; 1H NMR (400MHz, CDCl3,
TMS), d 0.64–0.89 (m, 4H, (CH2)2), 2.96–2.97 (m, 1H,
CH), 4.66 (s, 2H, CH2Cl), 7.40 (d, 1H, 8-H), 7.69 (d,
1H, 7-H), 7.71 (s, 1H, 5-H), 8.91 (s, 1H, 4-H). Anal.
(C14H12NO3Cl) C, H, N.
N-Cyclopentyl-6-(chloromethyl)-2-oxo-2H-1-benzopyran-
3-carboxamide (17). This was prepared according to the
general procedure (yield: 43%): mp 218–220 C (ethyl
acetate:petroleum ether 40–60 C); IR 3321 (N–H), 3037
(C–H arom), 2965, 2864 (C–H aliph), 1729 (CO lac-
tone), 1649 (CO amide), 1618, 1580, 1541 cmÿ1; 1H
NMR (80MHz, CDCl3, TMS), d 1.25–2.10 (m, 8H,
(CH2)4, 4.40 (m, 1H, CH), 4.65 (s, 2H, CH2Cl), 7.30 (d,
1H, 8-H), 7.65–7.75 (m, 2H, 5-H, 7-H), 8.70 (m, 1H,
NH), 8.80 (s, 1H, 4-H). Anal. (C16H16NO3Cl) C, H, N.
N-Cyclohexyl-6-(chloromethyl)-2-oxo-2H-1-benzopyran-
3-carboxamide (18). This was prepared according to the
general procedure (yield: 54%): mp 220–223 C (ethyl
acetate:petroleum ether 40–60 C); IR 3327 (N–H),
2930, 2854 (C–H aliph), 1733 (CO lactone), 1650
(CO amide), 1618, 1580, 1536, 1489, 1445, 1252, 1223
cmÿ1; 1H NMR (80MHz, CDCl3, TMS), d 1.20–1.95
(m, 10H, (CH2)5), 3.95 (m, 1H, CH), 4.60 (s, 2H,
CH2Cl), 7.35 (d, 1H, 8-H), 7.55–7.65 (d+s, 2H, 5-H,
7-H), 8.70 (m, 1H, NH), 8.85 (s, 1H, 4-H). Anal.
(C17H18NO3Cl) C, H, N.
N-Cycloheptyl-6-(chloromethyl)-2-oxo-2H-1-benzopyran-
3-carboxamide (19). This was prepared according to the
general procedure (yield: 38%): mp 207–211 C (ethyl
acetate:petroleum ether 40–60 C); IR 3324 (N–H),
2928, 2851 (C–H aliph), 1730 (CO lactone), 1647
(CO amide), 1618, 1579, 1535, 1173 cmÿ1; 1H NMR
(80MHz, CDCl3, TMS), d 1.20–2.00 (m, 12H, (CH2)6),
4.05 (m, 1H, CH), 4.65 (s, 2H, CH2Cl), 7.30 (d, 1H, 8-
H), 7.60-7.75 (m, 2H, 5-H, 7-H), 8.70 (m, 1H, NH), 8.80
(s, 1H, 4-H). Anal. (C18H20NO3Cl) C, H, N.
N-Cyclooctyl-6-(chloromethyl)-2-oxo-2H-1-benzopyran-
3-carboxamide (20). This was prepared according to the
general procedure (yield: 32%): mp 192–195 C (ethyl
acetate:petroleum ether 40–60 C); IR 3326 (N–H),
3062, 3034 (C–H arom), 2923, 2855 (C–H aliph), 1728
(CO lactone), 1647 (CO amide), 1618, 1579, 1533,
1363, 1243, 1174 cmÿ1; 1H NMR (400MHz, CDCl3,
TMS), d 1.60–1.94 (m, 14H, (CH2)7), 4.18–4.20 (m, 1H,
CH), 4.66 (s, 2H, CH2Cl), 7.41 (d, 1H, 8-H), 7.67–7.69
(d+s, 2H, 5-H, 7-H), 8.78–8.80 (m, 1H, NH), 8.88 (s,
1H, 4-H). Anal. (C19H22NO3Cl) C, H, N.
N-Cyclododecyl-6-(chloromethyl)-2-oxo-2H-1-benzopyran-
3-carboxamide (21). This was prepared according to the
general procedure (yield: 41%): mp 224–226 C (ethyl
acetate:petroleum ether 40–60 C); IR 3329 (N–H),
2944, 2863, 2840 (C–H aliph), 1731 (CO lactone), 1649
(CO amide), 1619, 1580, 1541, 1470 cmÿ1; 1H NMR
(400MHz, CDCl3, TMS), d 1.25–1.80 (m, 22H,
(CH2)11), 4.24–4.26 (m, 1H, CH), 4.66 (s, 2H, CH2Cl),
7.41 (d, 1H, 8-H), 7.68–7.70 (d+s, 2H, 5-H, 7-H), 8.65–
8.67 (m, 1H, NH), 8.88 (s, 1H, 4-H). Anal. (C23H30
NO3Cl) C, H, N.
N-Piperid-1-yl-6-(chloromethyl)-2-oxo-2H-1-benzopyran-
3-carboxamide (22). This was prepared according to the
general procedure (yield: 37%): mp 197–200 C (ethyl
acetate:petroleum ether 40–60 C); IR 3273 (N–H), 3042
(C–H arom), 2941, 2856, 2804 (C–H aliph), 1735 (CO
lactone), 1662 (CO amide), 1580, 1539, 1273, 1247,
1164 cmÿ1; 1H NMR (400MHz, CDCl3, TMS), d 1.46–
1.49 (m, 2H, N(C2H4)2CH2), 1.75–1.80 (m, 4H, N(CH2
CH2)2), 2.90 (t, 4H, N(CH2CH2)2), 4.65 (s, 2H, CH2Cl),
7.41 (d, 1H, 8-H), 7.68–7.71 (d+s, 2H, 5-H, 7-H), 8.94
(s, 1H, 4-H), 9.52 (s, 1H, NH). Anal. (C16H17N2O3Cl)
C, H, N.
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N,N0-Dipropyl-6-(chloromethyl)–2-oxo-2H-1-benzopyran-
3-carboxamide (23). This was prepared according to the
general procedure (yield: 41%): mp 118–124 C (ethyl
acetate:petroleum ether 40–60 C); IR 3045 (C–H
arom), 2970, 2932, 2873 (C–H aliph), 1715 (CO lac-
tone), 1631 (CO amide) cmÿ1; 1H NMR (80MHz,
CDCl3, HMDS), d 0.70 (m, 6H, 2* CH3), 1.55 (m, 4H,
2* CH2-CH2-CH3), 3.10 (t, 2H, N-CH2 aCH2CH3), 3.40
(t, 2H, N-CH2 bCH2CH3), 4.55 (s, 2H, CH2Cl), 7.25 (d,
1H, 8-H), 7.45 (s, 1H, 5-H), 7.50 (d, 1H, 7-H), 7.65 (s,
1H, 4-H). Anal. (C17H20NO3Cl) C, H, N.
6-(Chloromethyl)-2-oxo-3-piperidinocarbonyl-2H-1-benzo-
pyran-3-carboxamide (24). This was prepared according
to the general procedure (yield: 34%): mp 153–155 C
(ethyl acetate:petroleum ether 40–60 C); IR 3044 (C–H
arom), 2944, 2856 (C–H aliph), 1714 (CO lactone),
1640 (CO amide), 1580, 1445, 1255, 1237, 1178 cmÿ1;
1H NMR (400MHz, CDCl3, TMS), d 1.60–1.68 (m, 6H,
(CH2CH2)2CH2), 3.30–3.71 (m, 4H, (CH2CH2)2), 4.63
(s, 2H, CH2Cl), 7.35 (d, 1H, 8-H), 7.55 (s, 1H, 5-H), 7.59
(d, 1H, 7-H), 7.83 (s, 1H, 4-H). Anal. (C16H16NO3Cl) C,
H, N.
6-(Chloromethyl)-3-morpholinocarbonyl-2-oxo-2H-1-ben-
zopyran-3-carboxamide (25). This was prepared according
to the general procedure (yield: 37%): mp 210–212 C
(ethyl acetate:petroleum ether 40–60 C); IR 3044, 3027
(C–H arom), 2992, 2922, 2858 (C–H aliph), 1718 (CO
lactone), 1626 (CO amide), 1582, 1469, 1275, 1248,
1178 cmÿ1; 1H NMR (400MHz, CDCl3, TMS), d 3.39–
3.80 (m, 8H, (CH2CH2)2), 4.64 (s, 2H, CH2Cl), 7.37 (d,
1H, 8-H), 7.57 (s, 1H, 5-H), 7.62 (d, 1H, 7-H), 7.94 (s,
1H, 4-H). Anal. (C15H14NO4Cl) C, H, N.
2-Nitrophenyl 6-(chloromethyl)-2-oxo-2H-1-benzopyran-
3-carboxylate (26). This was prepared according to the
general procedure (yield: 37%): mp 163–164 C (aceto-
nitrile); IR 3077 (C–H arom), 1768 (CO ester), 1727
(CO lactone), 1609, 1576, 1548, 1374, 1349, 1242, 1204
cmÿ1; 1H NMR (400MHz, CDCl3, TMS), d 4.67 (s, 2H,
CH2Cl), 7.41–7.51 (m, 3H, 8-H, 4
0-H, 60-H), 7.72–7.77
(m, 3H, 5-H, 7-H, 50-H), 8.18 (dd, 1H, 30-H), 8.79 (s,
1H, 4-H). Anal. (C17H10NO6Cl) C, H, N.
3-Trifluoromethylphenyl 6-(chloromethyl)-2-oxo-2H-1-
benzopyran-3-carboxylate (27). This was prepared
according to the general procedure (yield: 46%): mp
162–163 C (acetonitrile); IR 3069 (C–H arom), 1772
(CO ester), 1756 (CO lactone), 1621, 1574, 1336,
1239, 1223, 1200 cmÿ1; 1H NMR (80MHz, CDCl3,
HMDS), d 4.55 (s, 2H, CH2Cl), 7.15–7.40 (m, 5H,
C6H4, 8-H), 7.55 (s, 1H, 5-H), 7.60 (d, 1H, 7-H), 8.65 (s,
1H, 4-H). Anal. (C18H10O4F3Cl) C, H.
3-Methoxyphenyl 6-(chloromethyl)-2-oxo-2H-1-benzo-
pyran-3-carboxylate (28). This was prepared according
to the general procedure (yield: 47%): mp 133–135 C
(CHCl3:petroleum ether 40–60
C); IR 3063 (C–H
arom), 1775 (CO ester), 1757 (CO lactone), 1622,
1609, 1574, 1489, 1377, 1245, 1224, 1147 cmÿ1; 1H
NMR (80MHz, CDCl3, HMDS), d 3.70 (s, 3H, OCH3),
4.55 (s, 2H, CH2Cl), 6.7–6.8 (m, 3H, 2
0-H, 40-H, 60-H),
7.10–7.35 (m, 2H, 8-H, 50-H), 7.55 (s, 1H, 5-H), 7.60 (d,
1H, 7-H), 8.60 (s, 1H, 4-H). Anal. (C18H13O5Cl) C, H.
3-Fluorophenyl 6-(chloromethyl)-2-oxo-2H-1-benzopyran-
3-carboxylate (29). This was prepared according to the
general procedure (yield: 52%): mp 195–197 C (aceto-
nitrile); IR 3070 (C–H arom), 1774 (CO ester), 1756
(CO lactone), 1709, 1622, 1609, 1573, 1486, 1444,
1380, 1240, 1223 cmÿ1; 1H NMR (80MHz, CDCl3,
HMDS), d 4.55 (s, 2H, CH2Cl), 6.90–7.35 (m, 5H,
C6H4, 8-H), 7.60 (s, 1H, 5-H), 7.65 (d, 1H, 7-H), 8.60 (s,
1H, 4-H). Anal. (C17H10O4FCl) C, H.
3-Bromophenyl 6-(chloromethyl)-2-oxo-2H-1-benzopyran-
3-carboxylate (30). This was prepared according to the
general procedure (yield: 37%): mp 177–178 C (aceto-
nitrile), IR 3086 (C–H arom), 3062 (C–H arom), 1771
(CO ester), 1724 (CO lactone), 1619, 1574, 1468,
1375, 1244 cmÿ1; 1H NMR (80MHz, CDCl3, HMDS),
d 4.55 (s, 2H, CH2Cl), 7.05–7.40 (m, 5H, C6H4, 8-H),
7.60–7.70 (s+d, 2H, 5-H, 7-H), 8.60 (s, 1H, 4-H). Anal.
(C17H10O4BrCl) C, H.
3-Chloro-5-methoxyphenyl 6-(chloromethyl)-2-oxo-2H-1-
benzopyran-3-carboxylate (32). This was prepared
according to the general procedure (yield: 50%): mp 184–
185 C (acetonitrile); IR 3064 (C–H arom), 1779 (CO
ester), 1758 (CO lactone), 1621, 1573, 1377, 1242,
1222, 1150 cmÿ1; 1H NMR (80MHz, CDCl3, HMDS), d
3.70 (s, 3H, OCH3), 4.55 (s, 2H, CH2Cl), 6.60–6.90 (m,
3H, C6H3), 7.30 (d, 1H, 8-H), 7.60 (s, 1H, 5-H), 765 (d,
1H, 7-H), 8.60 (s, 1H, 4-H). Anal. (C18H12O5Cl2) C, H.
2,3-Dichlorophenyl 6-(chloromethyl)-2-oxo-2H-1-benzo-
pyran-3-carboxylate (33). This was prepared according
to the general procedure (yield: 34%): mp 173–174 C
(ethyl acetate); IR 3051 (C–H arom), 1771 (CO ester),
1723 (CO lactone), 1620, 1572, 1450, 1433, 1374, 1238,
1215 cmÿ1; 1H NMR (400MHz, CDCl3, TMS), d 4.66
(s, 2H, CH2Cl), 7.25–7.31 (m, 2H, 5
0-H, 60-H), 7.41–7.44
(m, 2H, 8-H, 40-H), 7.72–7.74 (s+d, 2H, 5-H, 7-H), 8.80
(s, 1H, 4-H). Anal. (C17H9O4Cl3) C, H.
2,5-Dichlorophenyl 6-(chloromethyl)-2-oxo-2H-1-benzo-
pyran-3-carboxylate (34). This was prepared according
to the general procedure (yield: 40%): mp 197–199 C
(ethyl acetate); IR 3092, 3045 (C–H arom), 1769 (CO
ester), 1721 (CO lactone), 1621, 1573, 1474, 1372,
1241, 1220 cmÿ1; 1H NMR (400MHz, CDCl3, TMS),
d 4.66 (s, 2H, CH2Cl), 7.25 (d, 1H, 40-H), 7.35 (d, 1H,
60-H), 7.41–7.44 (m, 2H, 8-H, 30-H), 7.72–7.74 (s+d,
2H, 5-H, 7-H), 8.79 (s, 1H, 4-H). Anal. (C17H9O4Cl3) C,
H.
2,6-Dichlorophenyl 6-(chloromethyl)-2-oxo-2H-1-benzo-
pyran-3-carboxylate (35). This was prepared according
to the general procedure (yield: 43%): mp 177–178 C
(ethyl acetate); IR 3074 (C–H arom), 1773 (CO ester),
1720 (CO lactone), 1619, 1571, 1488, 1450, 1376, 1228
cmÿ1; 1H NMR (400MHz, CDCl3, TMS), d 4.66 (s, 2H,
CH2Cl), 7.22 (dd, 1H, 4
0-H), 7.40–7.43 (m, 3H, 8-H, 30-
H, 50-H), 7.72–7.74 (s+d, 2H, 5-H, 7-H), 8.55 (s, 1H, 4-
H). Anal. (C17H9O4Cl3) C, H.
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3,5-Dichlorophenyl 6-(chloromethyl)-2-oxo-2H-1-benzo-
pyran-3-carboxylate (36). This was prepared according
to the general procedure (yield: 48%): mp 208–209 C
(CHCl3); IR 3069 (C–H arom), 1778 (CO ester), 1762
(CO lactone), 1713, 1620, 1581, 1571, 1376, 1241
cmÿ1; 1H NMR (400MHz, CDCl3, TMS), d 4.66 (s, 2H,
CH2Cl), 7.21 (s, 2H, 2
0-H, 60-H), 7.31 (s, 1H, 40-H), 7.41
(d, 1H, 8-H), 7.70 (s, 1H, 5-H), 7.73 (d, 1H, 7-H), 8.70
(s, 1H, 4-H). Anal. (C17H9O4Cl3) C, H.
S-Phenyl 6-(chloromethyl)-2-oxo-2H-1-benzopyran-3-car-
bothioate (39). This was prepared according to the gen-
eral procedure (yield: 43%): mp 164–166 C (acetonitrile);
IR 3060, 3042 (C–H arom), 1724 (CO lactone), 1655
(CO thioester), 1568, 1178 cmÿ1; 1H NMR (80MHz,
CDCl3, HMDS), d 4.55 (s, 2H, CH2Cl), 7.30–7.60 (m,
6H, 8-H, C6H5), 7.60 (s, 1H, 5-H), 7.65 (d, 1H, 7-H),
8.50 (s, 1H, 4-H). Anal. (C17H11O3SCl) C, H, S.
N-(30-Chlorophenyl)-6-(chloromethyl)-2-oxo-2H-1-benzo-
pyran-3-carboxamide (40). This was prepared according
to the general procedure (yield: 38%): mp 219–220 C
(acetone); IR 3225 (N–H amide), 3080, 3040 (C–H
arom), 1707 (CO lactone), 1664 (CO amide), 1591,
1573, 1542, 1426, 1253 cmÿ1; 1H NMR (400MHz,
CDCl3, TMS), d 4.68 (s, 2H, CH2Cl), 7.13–7.16 (m, 1H,
40-H), 7.31 (dd, 1H, 50-H), 7.46 (d, 1H, 8-H), 7.54–7.56
(m, 1H, 60-H), 7.73–7.76 (s+d, 2H, 5-H, 7-H), 7.89–7.90
(m, 1H, 20-H), 9.00 (s, 1H, 4-H). Anal. (C17H11NO3Cl2)
C, H, N.
S-(30-Chlorophenyl) 6-(chloromethyl)-2-oxo-2H-1-benzo-
pyran-3-carbothioate (41). This was prepared according
to the general procedure (yield: 63%): mp 194–195 C
(acetonitrile); IR 3070, 3045 (C–H arom), 1712 (CO
lactone), 1652 (CO thioester), 1568, 1180 cmÿ1; 1H
NMR (400MHz, CDCl3, TMS), d 4.66 (s, 2H, CH2Cl),
7.40–7.45 (m, 4H, 8-H, 40-H, 50-H, 60-H), 7.52 (s, 1H, 20-
H), 7.71–7.72 (s+d, 2H, 5-H, 7-H), 8.55 (s, 1H, 4-H).
Anal. (C17H10O3SCl2) C, H, S.
Phenyl 2-oxo-2H-1-benzopyran-3-carboxylate (43). This
was prepared according to the general procedure (yield:
80%): mp 155–157 C (ethyl acetate); IR 3060 (C–H
arom), 1768 (CO ester), 1741 (CO lactone), 1715,
1610, 1243 cmÿ1; 1H NMR (400MHz, CDCl3, TMS), d
7.23–7.46 (m, 7H, C6H5, 6-H, 8-H), 7.66–7.72 (m, 2H, 5-
H, 7-H), 8.75 (s, 1H, 4-H). Anal. (C16H10O4) C, H.
Phenyl 6-(acetoxymethyl)-2-oxo-2H-1-benzopyran-3-car-
boxylate (44). This was prepared according to the general
procedure (yield: 46%): mp 188–190 C (ethyl acetate);
IR 3067 (C–H arom), 1733 (CO esters and lactone),
1628, 1580, 1493, 1250 cmÿ1; 1H NMR (80MHz,
CDCl3, TMS), d 2.05 (s, 3H, CH3), 5.10 (s, 2H, CH2),
7.10–7.40 (m, 6H, C6H5, 8-H), 7.60 (s, 1H, 5-H), 7.65 (d,
1H, 7-H), 8.75 (s, 1H, 4-H). Anal. (C19H14O6) C, H.
3-Chlorophenyl 6-methyl-2-oxo-2H-1-benzopyran-3-car-
boxylate (45). This was prepared according to the general
procedure (yield: 45%): mp 175–176 C (ethyl acetate);
IR 3078 (C–H arom), 1771 (CO ester), 1721 (CO
lactone), 1624, 1577, 1492, 1223 cmÿ1; 1HNMR (400MHz,
CDCl3, TMS), d 2.45 (s, 3H, CH3), 7.15–7.18 (m, 1H,
40-H), 7.27–7.32 (m, 3H, 8-H, 20-H, 60-H), 7.37 (dd, 1H,
50-H), 7.45 (s, 1H, 5-H), 7.51 (d, 1H, 7-H), 8.66 (s, 1H,
4-H). Anal. (C17H11O4Cl) C, H.
3-Chlorophenyl 2-oxo-2H-1-benzopyran-3-carboxylate (46).
This was prepared according to the general procedure
(yield: 68%): mp 170–171 C (ethyl acetate); IR 3086,
3061 (C–H arom), 1767 (CO ester), 1721 (CO lac-
tone), 1611, 1299, 1217 cmÿ1; 1H NMR (400MHz,
CDCl3, TMS), 7.15–7.18 (m, 1H, 4
0-H), 7.27–7.43 (m,
5H, 6-H, 8-H, 20-H, 50-H, 60-H), 7.67–7.74 (m, 2H, 5-H,
7-H), 8.74 (s, 1H, 4-H). Anal. (C16H9O4Cl) C, H.
3-Chlorophenyl 6-(acetoxymethyl)-2-oxo-2H-1-benzo-
pyran-3-carboxylate (47). This was prepared according
to the general procedure (yield: 30%): mp 152–154 C
(ethyl acetate:petroleum ether 40–60 C); IR 3066 (C–H
arom), 1735 (CO esters and lactone), 1628, 1579, 1474,
1249 cmÿ1; 1H NMR (400MHz, CDCl3, TMS), d 2.14
(s, 3H, CH3), 5.18 (s, 2H, CH2), 7.15–7.18 (m, 1H, 4
0-
H), 7.27–7.30 (m, 2H, 20-H, 60-H), 7.36 (d, 1H, 8-H),
7.39–7.43 (m, 1H, 50-H), 7.69–7.72 (d+s, 2H, 5-H, 7-H),
8.73 (s, 1H, 4-H). Anal. (C19H13O6Cl) C, H.
Enzymatic studies
Bovine a-CT and HLE were purchased from Sigma and
Elastin Products Co., respectively. Their active site
concentrations were determined by active-site titration.16
The proteases were assayed spectrophotometrically
using p-nitroanilide substrates (Sigma): succinylalanyl-
alanylprolylphenylalanyl p-nitroanilide and methoxy-
succinylalanylalanylprolylvalyl p-nitroanilide for a-CT
and HLE, respectively. The reactions were performed
in 0.025M sodium phosphate, 0.05M NaCl at pH 7.5
for a-CT and 0.1M Hepes, 0.5M NaCl, 0.01%
(v/v) Tween 80 at pH 8.0 for HLE. Assays contained
10% (v/v) DMSO and were run at 25 C in a spectro-
photometer Lambda 5 (Perkin–Elmer) or UVIKON
941 (Kontron), both equipped with a thermostatted cell-
holder.
Suicide substrate inactivation can be represented by the
minimum scheme above, E and I being the free forms of
enzyme and inhibitor, E*I a kinetic chimere of the
Michaelis complex and the acyl-enzyme, E-I the inacti-
vated enzyme and P the product of hydrolysis of I. The
kinetic constants kinact and KI were determined using the
preincubation method or the progress curve method.38
Linear and non-linear regression fits of the experimental
data to the equations were performed with Kaleida-
graph version 3.0.1 (Abelbeck Software). At low inhi-
bitor concentrations, the ratio kinact/KI was obtained as
kobs/[I]. For the preincubation method, the enzyme and
inhibitor concentrations were: [a-CT]0=7, 12.5 or
100 nM, [I]0=0.25–100 mM, [HLE]0=20 nM, [I]0=0.6–
20 mM. For the progress curve method, the experimental
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conditions were: [a-CT]0=12.5 nM, [S]0=100 or 200mM,
[I]0=0.01–10 mM.
The partition ratio r=kc/kinact which represents the
average number of enzyme ‘turnovers per inactivation’
was obtained by plotting the residual activity at infinite
time of an enzyme–inhibitor mixture versus the ratio
[I]0/[E]0. The intercept of the linear plot obtained with
the x axis is equal to r+1.39
Hydroxylamine reactivation assays were performed by
treating inactivated a-CT solutions with 0.5M hydroxyl-
amine at pH 7.5 and 25 C during 30min. Enzyme
activity of aliquots was monitored and compared to a
control.
In order to perform the amino acid analysis of native
and inactivated a-CT by 31 and 34, the enzyme samples
were dried under vacuo and hydrolyzed by 6 N HCl at
105 C during 23 h. The amino acid mixtures were then
modified using phenylisothiocyanate (PITC), analyzed
by HPLC on a PICO-TAG column (3.9150mm,
WATERS) and compared to a sample of a standard
amino acid mixture treated according to the same pro-
cedure. The determination of the amino acid composi-
tion was based on the presence of 4 tyrosine residues.
X-Ray crystallography
Crystals of 30, C17H10O4BrCl, Mr=393.6, were
obtained by slow evaporation of a concentrated solu-
tion in CH3CN. A crystal measuring 0.470.28
0.025mm was selected for the crystallographic study:
monoclinic, P21, a=6.248(1) A˚, b=7.618(1) A˚, c=
15.975(2) A˚, b=94.87(1), V=757.6(2) A˚,3 Z=2, =
5.488mmÿ1, Dx=1.725 g cmÿ3, l(CuKa)=1.54178 A˚,
F(000)=392, T=290 K, 1893 unique reflections
(Rint=0.015), R1=0.0338 for 1798 Fo>4s(Fo) and
wR2=0.0947, GOF=S=1.028. Absorption eects were
corrected using analytical methods, Tmax=0.763 and
Tmin=0.245. Full matrix least-squares on F
2.
Calculation
All the calculations have been performed at the ab initio
RHF level using the minimal basis set MINI-10.40,41
They were performed with Gaussian 9442 on two com-
puters, a Dec Alpha 8400 8-processor and a Dec Alpha
4100 4-processor running Digital Unix. The starting
geometries were sketched drawn by standard fragments
and then completely optimized following all the 3Nÿ6
degrees of freedom either for the minima or the tran-
sition state structures. For each equilibrium structure,
the thermochemistry data are derived from the analy-
tical frequency calculation at 298.15 K and 1 atm. The
conformational analysis of 37, 38 and 39 has been per-
formed following the rotatable bond of the carbonyl
moiety of the substituent using a stepsize of 30 degrees.
At each point, the 3Nÿ5 degrees of freedom have been
reoptimized allowing us to locate the positions of the
extrema, i.e., the minima and the transition state struc-
ture(s) between them.
Supporting information available
X-Ray crystallographic data, including positional para-
meters, bond distances, bond angles, torsion angles, and
anisotropic displacement parameter expressions for 30
and all the equilibrium structure geometries as well as
frequency calculation and/or Z-matrices are available
on request from the authors.
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